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1  | INTRODUC TION
The newest drugs to target chronic lymphocytic leukaemia (CLL) in-
clude the inhibitors of the intracellular B-cell receptor signalling (BCR 
inhibitor)1 and the BCL2 inhibitor venetoclax.2,3 B-cell receptor signal-
ling inhibitors incorporate the direct BTK inhibitor ibrutinib and the 
inhibitor of PI3K-delta,4 a BTK downstream effector, idelalisib. Both 
ibrutinib and idelalisib have entered the clinical field with impressive 
results in chemotherapy-refractory CLL patients. However, both drugs 
are less effective with p53 mutated/deleted CLL cells. This type of 
CLL remains highly challenging form which should better benefit from 
the treatment with the BCL2 inhibitor, venetoclax, which acts as a 
pro-apoptotic trigger.5 With such a remarkable option of drugs and 
the possibility to target p53 mutated/deleted clones, CLL should be 
considered as an easily treatable cancer and the intent to eradicate the 
disease no longer a fleeting mirage. Unfortunately, cases of resistance 
to each of these novel drugs have already been reported and mech-
anisms of resistance deeply investigated.2,6-8 Interestingly, however, 
no recurrent abnormalities or mutations have been associated with a 
specific pattern of resistance, posing some concerns on how resistant 
patients can be further treated.
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Abstract
The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically 
improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance 
to these therapies has already been reported due to non-recurrent changes in onco-
genic pathways and genes expression signatures. In this study, we investigated the 
cooperative role of the BCL2 inhibitor venetoclax and the BRD4 inhibitor JQ1. In par-
ticular, we found that JQ1 shows additional activity with venetoclax, in CLL cell lines 
and in ex vivo isolated primary CD19+ lymphocytes, arguing in favour of combination 
strategies. Lastly, JQ1 is also effective in venetoclax-resistant CLL cell lines. Together, 
our findings indicated that the BET inhibitor JQ1 could be a promising therapy in CLL, 
both as first-line therapy in combination with venetoclax and as second-line therapy, 
after the emergence of venetoclax-resistant clones.
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It should be noted that in all the trials with these new drugs in 
the CLL context, idelalisib, ibrutinib and venetoclax are always used 
as single agents.9 In the dynamic process of clonal evolution of can-
cer, the administration of a single agents could simply represent a 
selective pressure to promote the evolution of sub-clones, thereby 
selecting those with a resistant behaviour.
It is indeed mandatory to design combinatorial strategies to be 
administrated upfront the development of resistant clones or alter-
natively move into a step by step (drug by drug) process.
Venetoclax resistant clones originate from cells where a set of 
genes are differentially expressed when compared with parental 
clones. Among these, the major determinants are MCL-1 and BCL-
XL.
10,11 This means that, parallel to apoptosis promotion through 
BCL2 modulation, venetoclax affects the overall gene expression 
machinery. Some of these genes may favour cells to survive.
In line with these considerations, a perfect drug to associate 
with venetoclax would be a drug that transiently impairs gene ex-
pression during venetoclax administration, preventing the activation 
of compensatory mechanisms that inhibit or affect the induction of 
apoptosis.
The bromodomain and extra terminal BET family proteins com-
prise four members (BRD2, BRD3, BRD4 and the testis-specific 
BRDT), which contain tandem bromodomains that allow to interact 
with acetylated lysines of histones and regulate gene transcription 
of relevant oncogenes, such as MYC, CDK genes, cyclin D1 and 
BCL2.12-14
Currently, various BET inhibitors have been developed and few 
of them are under investigation in clinical trials.15,16 However, while 
BET inhibitors were consistently described as highly effective drugs 
in in vitro experiments, few in vivo observations and early clinical 
trial reports had already posed some concerns regarding the poten-
tial development of resistance to BET inhibitors, when administrated 
as single agents.16 In the case of AML, for instance, treatment with 
BET inhibitors promotes resistance through the up-regulation of 
BET target genes.17
In this report, we have investigated the mechanisms of veneto-
clax resistance in CLL. In addition, we have demonstrated the ef-
ficacy of BET inhibitors, JQ1, in combination with venetoclax and 
against venetoclax resistant clone.
2  | E XPERIMENTAL PROCEDURES
2.1 | Cells and primary human samples
Human MEC-1 cell line was gently provided by Prof. Deaglio 
(University of Turin)18,19 and was grown in IMDM medium (Life 
Technologies) supplemented with 10% foetal bovine serum (FBS; 
Sigma Aldrich), 1% penicillin/streptomycin (EuroClone) and main-
tained at 37°C in a 5% CO2 humidified atmosphere. EHEB cell line 
was purchased from DSMZ and was maintained in RPMI medium 
10% FBS and 1% penicillin/streptomycin (EuroClone). The lymphoid 
nature of this cell line was authenticated by flow cytometry (CD19+ 
positivity).
Human samples were collected from untreated CLL patients at 
the San Luigi Hospital (Orbassano, Italy), following informed consent 
and with obscured identity, as processed as previously described.20 
Briefly, CLL cells were isolated from peripheral blood samples by 
density gradient centrifugation accordingly to Ficoll procedure 
(Sigma-Aldrich). Following centrifugation at 400 g for 20 minutes, 
CD19+ lymphocytes were isolated accordingly to the Miltenyi Biotec 
protocol (Miltenyi Biotec, #130-050-301).
The project was reviewed and approved by the institutional eth-
ical committee (code #10/2013).
2.2 | Gene expression analysis
RNA was extracted from cells using TRIzol as described.21 1 μg of 
total RNA was used for reverse transcription with iScript cDNA 
Synthesis Kit (Bio-Rad) according to the manufacturer's protocol. 
Real-time PCR was performed with iQ SYBR Green (Bio-Rad) with 
the following primers:
• BRD2_for: 5′-GGAAGATGAGGAGGACGAGG-3′;
• BRD2_rev: 5′-TGGGCTTGGATATTGGACCC-3′;
• BRD4_for: 5′-ATACCTGCTCAGAGTGGTGC-3′;
• BRD4_rev: 5′-TGTTCCCATATCCATAGGCGT-3′;
• hHuPO FW: 5′-GCTTCCTGGAGGGTGTCC-3′;
• hHuPO RV: 5′-GGACTCGTTTGTACCCGTTG-3′
Real-time PCR parameters were cycle 1, 95°C-3 minutes; cycle 
2, 95°C-15 seconds, 60°C-30 seconds for 40 cycles. The 2−ΔΔCT 
method was used to analyse the data. hHuPO was used to normalize 
the results.
2.3 | Cell proliferation assay, cell-cycle analysis and 
assessment of apoptosis
Cells were plated in 96-well plates at the density of 1.5 × 103 cells/
well. Proliferation was evaluated by CellTiter-Glo (Promega) follow-
ing the manufacturer's instructions. Cells were plated at a density of 
2.5 × 105 in 6-well plates and then treated or not with JQ1 (0.5 μmol/L) 
for 2 days. After being harvested and washed with PBS, cells were 
treated with RNAse (0.25 mg/mL) and stained with propidium iodide 
(50 μg/mL). The cell-cycle distribution in G0/G1, S and G2/M phase 
was calculated using the CellQuest program (BD Biosciences).
Apoptosis was measured by flow cytometry after staining with 
Annexin V. Briefly, after 2 days with or without JQ1 (0.5 μmol/L), 
venetoclax (0.5 μmol/L) or a combination of these two drugs. Cells 
were washed in PBS and incubated for 15 minutes at room tem-
perature in HEPES buffer solution (10 mmol/L HEPES, pH 7.4, 
140 mmol/L NaCl, 2.5 mmol/L CaCl2) with 2.5 μL Annexin V Fitc/PI 
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(BD Biosciences). Cells were analysed by FACScan using CellQuest 
Software (BD Biosciences).
The combination index (CI) for drug combination was calculated 
with the available software CalcuSyn. CI values < 1.0 indicate a syn-
ergistic interaction of the two drugs in the combination.
2.4 | Cell lysis and Western blot assay
Cells were lysed in lysis buffer containing 150 mmol/L NaCl, 
1 mmol/L EDTA, 50 mmol/L Hepes (pH 7.5), 1% Triton X-100 and 
10% glycerol. Protein lysates were resolved in 4%-15% SDS-PAGE 
gels transferred into nitrocellulose filters. Proteins were visualized 
with peroxidase-conjugated secondary antibodies and chemilumi-
nescence reagent (BIORAD, #170-5060).
2.5 | Anchorage-independent cell-growth assay
Cells were suspended in 0.45% type VII low-melting agarose in 10% 
IMDM at a density of 5 × 103 cells/well and plated on a layer of 0.9% 
type VII low-melting agarose in 10% IMDM in 6-well plates then cul-
tured at 37°C with 5% CO2. After 2 weeks, colonies were counted, 
and images were acquired at 5× magnification.
2.6 | Antibodies and inhibitors
GAPDH (#5174), pERK1/2 (# 9101S), ERK1/2 (# 4695S), pAKT (# 
4060S) and AKT (#4685) were from Cell Signalling Technologies; 
c-MYC (sc40) and BCL-2 (sc-7382) were from Santa Cruz; VINCULIN 
(SAB4200080); JQ1 and venetoclax inhibitors were from Selleckchem.
F I G U R E  1   Treatment with JQ1 
inhibits growth and survival in CLL cell 
lines. A, B, MEC-1 and EHEB cells were 
cultured in the presence or absence of 
JQ1 and cell counts were measured every 
48 h for 144 h. C, D, Cell-cycle status of 
MEC-1 and EHEB cells following 48 h of 
treatment with JQ1, as indicated. E, F, 
MEC-1 and EHEB cells were treated with 
JQ1, as indicated, for 48 h. The percent 
of apoptosis was determined by staining 
with Annexin V/PI and flow cytometry. 
Columns represent the mean apoptosis 
of 3 independent experiments. G, H, 
upper panel: Western immunoblot of 
MEC-1 and EHEB cells treated with the 
indicated concentrations of JQ1 for 48 h. 
Immunoblot analyses were conducted 
for the expression levels of c-MYC; lower 
panel: real-time PCR analysis of BRD2 and 
BRD4 mRNA levels in MEC-1 and EHEB 
cell lines treated for 48 h with different 
JQ1 concentrations, as indicated
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F I G U R E  2   Combined treatment with JQ1 and venetoclax exerts synergistic lethal activities against CLL cell lines. A, B, MEC-1 (left) and 
EHEB (right) cells were cultured in the presence or absence of JQ1 and venetoclax at indicated concentration. Cell counts were measured 
every 48 h for 144 h by CTG assay. C, D, Bcl2 protein expression MEC-1 (C) and EHEB (D) upon treatment with venetoclax, JQ1 and the 
association. E, F, MEC-1 (left) and EHEB (right) cells were treated with JQ1 and venetoclax for 48 h. The percent of Annexin V/PI-positive 
apoptotic cells was determined by flow cytometry. Columns, mean of 3 independent experiments. G, H, Representative immunoblots of 
MEC-1 and EHEB cells treated with the JQ1 for 48 h. Immunoblot analyses were conducted for the expression levels of p-ERK1/2, ERK1/2, 
p-AKT, AKT and vinculin in the cell lysates
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2.7 | Statistical analysis
Two-sided Student's t test or two-way ANOVA with Bonferroni 
post-test were calculated using GraphPad Prism v5.0d (GraphPad 
Software). P-values < .05 were considered statistically significant. 
*P < .05; **P < .01; ***P < .001. All mean values (±SD) are from 3 
independent experiments.
3  | RESULTS
3.1 | Treatment with JQ1 inhibits growth and 
survival in CLL cell lines
We first determined the JQ1 effect on the growth and survival of both 
in MEC-1 and EHEB CLL cell lines. JQ1 treatment was associated with 
marked reduction in cellular viability (Figure 1A,B) and increased the 
percentage of G1-phase of the cell cycle (Figure 1C,D). Treatment with 
JQ1 induced dose-dependently apoptosis of CLL cells (Figure 1E,F 
and Figure S1A). Western analysis of the protein lysates showed that 
treatment with JQ1 reduced the protein expressions of c-MYC protein 
(Figure 1G,H, upper panel) in MEC-1 and EHEB cell lines. Accordingly, 
the qPCR analysis showed that JQ1 treatment attenuated the mRNA 
expression of BRD4 (Figure 1G,H, lower panel), which is a direct regu-
lator of c-myc expression. All together these data are in line with most 
of the observations with other cancers and suggest that BET inhibitors 
could be exploited also in the CLL context.
3.2 | Combined treatment with JQ1 and venetoclax 
exerts synergistic lethal activities against CLL 
cell lines
To define whether pharmacological inhibition of BRD4 synergies with 
venetoclax regimen, we treated both TP-p53-mutated-MEC1 and 
TP-p53 wild-type-EHEB cells with a combination of venetoclax plus 
JQ1, observing a significantly higher reduction in cell viability com-
pared to single treatments (Figure 2A,B). Moreover, due to the ability of 
JQ1 to modulate BCL2 expression,22 we observed that the association 
with venetoclax plus JQ1 favours a profound BCL2 downmodulation 
(Figure 3C,D) which may be the cause of such a remarkable apoptosis 
induction (Figure 2E,F and Figure S2A). Notably, treatment with JQ1 and 
venetoclax in combination synergistically induced apoptosis of CLL cell 
lines, with combination index (CI) <1.0 (Figure S2B). To recapitulate the 
mechanism of this synergy, it is worth to note that in some previously 
published works, it was showed that EGFR and insulin receptor families 
are direct targets of BRD4 in several cancer models. This strongly sug-
gests that, by blocking BRD4, BET inhibition can regulate the PI3K signal 
in cancer cells.23 However, in xenograft models of endometrial can-
cer, JQ1 significantly increases the expression of PTEN, favouring the 
block of the PI3K/AKT signalling pathway.24 Very recently it was dem-
onstrated that BRD4 inhibition induces apoptosis and growth arrest in 
glioblastoma cells via VEGF/PI3K/AKT regulation.25 Furthermore, JQ1 is 
also effective to reduce the levels of p-Erk 1/2 in mouse models of pan-
creatic cancer and in anaplastic thyroid cancer cells where is often over-
activated. Similar results were obtained also in ovarian cancer cells.26-28
Accordingly, Western blot analysis showed that only JQ1 and not 
venetoclax reduced phosphorylation of ERK1/2 and AKT, potentially 
explaining the synergy of drugs in impairing CLL survival from a reg-
ulatory point of view (Figure 2G,H).
Altogether, these data indicate that treatment of CLL cells with 
BETi enhances the susceptibility to venetoclax.
3.3 | Co-treatment with JQ1 and venetoclax 
affects the viability of ex vivo human CLL cells
To assess whether the combinatorial therapy may affect primary 
CD19 positive lymphocytes from CLL patients, we treated freshly 
isolated CD19 positive CLL cells with JQ1, and venetoclax alone or 
F I G U R E  3   Co-treatment with JQ1 
and venetoclax affects the viability of 
ex vivo human CLL cells. A, Primary CLL 
cells were treated with JQ1 1 µmol/L, 
0.5 µmol/L venetoclax alone or in 
combination for 72 h. The percent of 
non-viable cells was determined by 
Annexin V staining and flow cytometry. B, 
upper panel: representative immunoblots 
of primary CLL cells treated with the 
indicated inhibitors for 72 h. Immunoblot 
analyses were conducted for the 
expression levels of BCL2 and vinculin in 
the cell lysates; lower panel: quantification 
of all analysed patients
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the combination of the two drugs. Supplementary Table  resumes 
the main features of CLL patients used in ex vivo experiments. 
Consistent with our previous observation, the combination is associ-
ated with a marked apoptosis induction and a pronounced reduction 
in BCL2 (Figure 3A,B and Figure S3A). These findings suggest that, 
as compared with treatment with each agent alone, co-treatment 
with JQ1 and venetoclax markedly induced apoptosis and could pre-
vent the development of resistant clones.
3.4 | JQ1 treatment is effective against venetoclax-
resistant CLL cells
Lastly, we investigated the efficacy of JQ1 in venetoclax-resistant 
clones. We established MEC-1 resistant cells to venetoclax by cul-
turing MEC-1 cells in the continuous presence of escalating doses 
of venetoclax (Figure 4A). MEC-1 resistant cells exhibited signifi-
cantly higher IC50 values for venetoclax (MEC-1:3.987 µmol/L 
vs MEC-1R: 13.96 µmol/L; Figure 4B). Colony formation assay 
further supports the resistance of MEC-1 cells to venetoclax 
(Figure 4C).
Importantly, JQ1 treatment inhibited proliferation (Figure 4D), 
significantly increased cell death (Figure 4E) and abrogated colony 
formation (Figure 4F). Finally, Western analysis showed that JQ1 ab-
rogate phosphorylation of ERK1/2 and AKT, suggesting that the an-
ti-tumour effect of BRD inhibition in venetoclax-resistant cells could 
depend on an impairment of this protein activity (Figure 4G). Lastly, by 
treating primary CD19 cells collected from a patient with venetoclax 
resistant disease, the apoptotic response is slightly increased (Figure 
S4A,B). Overall, these data suggest that BRD inhibition could be an 
intriguing second-line therapy regimen in CLL, in the case of emer-
gence of venetoclax resistance, but further investigations are needed.
4  | DISCUSSION
Dissecting the process of resistance to targeted therapies is impor-
tant to define new therapeutic strategies. Our data demonstrated 
F I G U R E  4   JQ1 treatment is effective 
against venetoclax-resistant CLL cells. A, 
Schematic representation of venetoclax-
resistant MEC-1 clones generation. B, 
Dose-response curves of MEC-1 cells lines 
treated for 48 h with JQ1 and analysed 
by CTG assay; IC-50 values of venetoclax 
in MEC-1 sensitive and resistant cells. C, 
Left panel: representative images of soft-
agar growth assay in MEC-1 cells treated 
with different venetoclax concentrations 
(0.005-0.5-2.5-5 µmol/L) for 11 d 
and quantification of soft agar colony 
formation; right panel: quantification 
of soft agar colony formation in MEC-1 
cells treated as previously described. 
D, Cells were cultured in the presence 
or absence of JQ1 and cell counts were 
measured every 48 h for 144 h by CTG 
assay. E, venetoclax resistant cells were 
treated with JQ1 72 h. The percent 
of apoptotic cells was determined by 
Annexin V staining and flow cytometry. F, 
Representative images and quantification 
of soft agar colony formation of 
venetoclax-resistant cells after 15 d of 
treatment with 0.5 µmol/L venetoclax 
and 0.5 µmol/L JQ1. G, Representative 
immunoblots of MEC-1 and EHEB 
cells treated with the JQ1 for 48 h. 
Immunoblot analyses were conducted 
for the expression levels of p-ERK1/2, 
ERK1/2, p-AKT, AKT and vinculin in the 
cell lysates
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that (a) the BET inhibitor JQ1 has an anti-tumour effect in CLL; 
(b) the combinatorial treatment of venetoclax plus JQ1 highly im-
proves the apoptotic effect of single treatments, both in cell lines 
and patient-derived models; (c) CLL cell line MEC-1 can easily 
develop resistance to venetoclax; (d) JQ1 is strongly efficacious 
as second-line strategy, in the case of emergence of venetoclax-
resistant clones.
Overall, these data raise some concerns on the utility of sin-
gle agents' schedules with new drugs in CLL, and potentially in 
other cancers. While chemotherapy was historically designed as a 
poly-chemotherapy, where various agents target different mecha-
nisms of cancer maintenance, new drugs were referred to the para-
digm of the precision medicine due to high selectivity and precision.
While selectivity may be a hallmark of drug safety, the innate 
genetic and epigenetic heterogeneity of cancer suggest that dif-
ferent biological mechanisms cooperate to sustain human cancers 
and therefore a single-drug approach is insufficient to eradicate 
them.
Clinical data, biological experiments and our data have indeed 
demonstrated that the single administration of these drugs is far 
away from the dream to eradicate CLL, or, better to cure CLL. Our 
data support the rational of combinatorial strategies to be ad-
ministrated up-front the development of resistances. Conversely, 
whether resistant clones are already emerged, second-line treat-
ment with targeted agents can still be worth. We believe that 
venetoclax plus BET inhibitors may represent a highly effective 
strategy to eradicate CLL. In particular, combinatorial therapy 
venetoclax plus Beti should be considered as a challenging ap-
proach to treat those patients with a highly aggressive form of 
CLL, those with mutant TP53, or to enhance the efficacy of vene-
toclax-base therapy in those patients where responses are partial. 
Lastly, it should be also considered that therapies with venetoclax, 
as with ibrutinib and idelalisib, appear to last indefinitely. An in-
tensification schedule may eventually offer the change to limit the 
duration of the therapy allowing to eradicate the disease rather 
than controlling it.
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